Phosphodiesterase 5 inhibitors effects on adaptation to high altitude, hape prevention and treatment: a literature review
Abstract
Introduction: High-altitude pulmonary edema (HAPE) is a life-threatening, non-cardiogenic form of pulmonary edema that typically occurs within 2-4 days after rapid ascent above 2,500 meters. It is characterized by hypoxia-induced pulmonary hypertension, increased capillary hydrostatic pressure, and defected alveolar-capillary barrier integrity. Current preventive strategies include gradual ascent and acclimatization, while descent and supplemental oxygen remain the mainstays of treatment. Pharmacological options, including phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil and tadalafil, appear as promising agents due to their pulmonary vasodilatory effects mediated via the nitric oxide (NO)–cGMP pathway.
Description of the state of knowledge: This review synthesizes findings from clinical trials, case series, and mechanistic studies published in the last three decades to evaluate the efficacy and safety of PDE5 inhibitors in both the prevention and treatment of HAPE. Evidence indicates that sildenafil and tadalafil effectively reduce pulmonary artery pressure, improve oxygenation, and preserve endothelial barrier function under hypoxic conditions. Their prophylactic use significantly lowers HAPE incidence in high-risk individuals, while therapeutic administration has demonstrated clinical improvement in established cases, particularly when nifedipine use is contraindicated. However, results from some high-altitude trials remain inconclusive, and individual…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.